Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.

• Status: Not yet recruiting
• Trial end date: 2020-07-30
• Target enrollment: 0
• Participant gender: All

Summary

There is no specific antiviral treatment recommended for COVID-19, and no vaccine is currently available. Baricitinib, an anti-Janus kinase inhibitor (anti-JAK) acting against JAK1 and JAK2. The drug was found capable to reduce or interrupt the passage of the virus into target cells, and to inhibit the JAK1- and JAK2-mediated cytokine release. The drug was licensed for the treatment of rheumatoid arthritis at the daily dose of 4 mg/orally, with excellent results in terms of clinical response and a good safety profile. Since baricitinib does not interact with antivirals due to its prevalent renal elimination, it may be used in combination.The evidence on the advantageous action of baricitinib on viral entry and cytokine outbreak constituted the rationale to perform a trial on patients with mild to moderate COVID-19 infection receiving baricitinib combined with antiviral therapy.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital of Prato
• Treatments: Antiviral Agents; Lopinavir; Ritonavir

Criteria

Inclusion Criteria:

• All consecutive patients with mild to moderate COVID-19 infection

• Age >18 years,

• Clinical diagnosis of COVID19 infection

• Patients should present fever, cough and myalgia and weakness and radiological findings of pneumonia.

• All patients should be willing and able to provide written informed consent prior to performing study procedures.

Exclusion Criteria:

• Age less than 18

• History of thrombophlebitis.

• Patient with latent tuberculosis infection (Quantiferon test).

• Pregnancy and lactation.